AI-generated summary
The authors report a retrospective clinical study of 35 patients with moderate meibomian gland dysfunction treated with the C.STIM intense pulsed light device over three sessions. Non-invasive break-up time increased significantly from baseline to three months, and no adverse events were noted. The authors note that a randomized controlled trial is needed to validate these results.
- Participants
- 35
- Who or what was studied
- Patients with moderate meibomian gland dysfunction
- Limits stated in the abstract
- The study was retrospective, and the authors state that a randomized controlled trial is needed to validate the results.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 8J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Randomized controlled trial, Adverse event, Dry eye, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.